PILA PHARMA’s clinical development candidate, XEN-D0501
PILA PHARMA in March 2016 purchased a clinical ready TRPV1 antagonist, XEN-D0501 previously owned by Ario Pharma Ltd (Cambridge, United Kingdom).
The TRPV1 antagonist XEN-D0501 has previously been investigated in 6 clinical studies and has been found to be exceptionally well tolerated in man.
The TRPV1 target (also called the “chili-receptor”) has been shown to have applications across pain and inflammatory diseases and is speculated to have a role in diabetes as well.
PILA PHARMA is planning to undertake a fast-track clinical development program, assessing the efficacy and safety of XEN-D0501 in treatment of type 2 diabetes.
The target product profile of PILA PHARMAs anti-diabetic TRPV1 antagonists is to effectively reduce blood glucose to near-normal levels via a dual regulation of insulin secretion and insulin sensitivity as well as regulating blood lipids and bodyweight thereby eventually reducing the overall risk of cardio-vascular disease”.
In addition to the development candidate, PILA PHARMA is the owner of use-patents giving the exclusive right to treat diabetes and obesity with TRPV1 antagonists (LINK to patents).